Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
To arise and progress, cancers need to evade immune elimination. Consequently, progressing tumors are often MHC class I (MHC-I) low and express immune inhibitory molecules, such as PD-L1, which allows them to avoid the main antitumor host defense, CD8+ T cells. The molecular mechanisms that led to these alterations were incompletely understood. In this study, we identify loss of the transcription factor IRF2 as a frequent underlying mechanism that leads to a tumor immune evasion phenotype in both humans and mice. We identified IRF2 in a CRISPR-based forward genetic screen for genes that controlled MHC-I Ag presentation in HeLa cells. We then found that many primary human cancers, including lung, colon, breast, prostate, and others, frequently downregulated IRF2. Although IRF2 is generally known as a transcriptional repressor, we found that it was a transcriptional activator of many key components of the MHC-I pathway, including immunoproteasomes, TAP, and ERAP1, whose transcriptional control was previously poorly understood. Upon loss of IRF2, cytosol-to–endoplasmic reticulum peptide transport and N-terminal peptide trimming become rate limiting for Ag presentation. In addition, we found that IRF2 is a repressor of PD-L1. Thus, by downregulating a single nonessential gene, tumors become harder to see (reduced Ag presentation), more inhibitory (increased checkpoint inhibitor), and less susceptible to being killed by CD8+ T cells. Importantly, we found that the loss of Ag presentation caused by IRF2 downregulation could be reversed by IFN-stimulated induction of the transcription factor IRF1. The implication of these findings for tumor progression and immunotherapy are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Irf2 was a transcriptional activator of many key components of the major histocompatibility complex class I antigen presentation. 21”
From Single-Cell RNA Sequencing to Dissect the Immunological Network of Autoimmune Myocarditis. (2020) · cites this paper as [21]
In the citing paper
“A positive correlation between IRF2 expression and MHC I has been observed in many human tumors, including CRC [212].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [212]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548 · cited 1×
“32 (20) was used to remove 59 or 39 stretches of bases having an average quality of ,20 in a window size of 10.”
MethodPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658
Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E., & Storey, J. D. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts034 · Cited by 6,231 · cited 1×
“0) (23, 24) with default parameters and a model that specified different replicates as batches.”
BackgroundDarnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080
Cited by
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Melief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636568 · Cited by 1,077
“, breast, NSCLC, prostate, colorectal, and uterine) downregulate IRF2 expression, which results in an immune evasion phenotype with MHC I low and PD-L1 high expression (69).”
BackgroundInfluentialSelf-citationAntigen presentation in cancer — mechanisms and clinical implications for immunotherapy
Yang, K., Halima, A., & Chan, T. A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00789-4 · Cited by 321
Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response
Taylor, B. C., & Balko, J. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844866 · Cited by 298
Interferon regulatory factor 1 (IRF1) and anti-pathogen innate immune responses
Feng, H., Zhang, Y.-B., Gui, J.-F., Lemon, S. M., & Yamane, D. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009220 · Cited by 289
Grabowski, M. M., Sankey, E. W., Ryan, K. J., Chongsathidkiet, P., Lorrey, S. J., Wilkinson, D. S., & Fecci, P. E. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03483-y · Cited by 270
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification
Montironi, C., Castet, F., Haber, P. K., Pinyol, R., Torres-Martin, M., Torrens, L., Mesropian, A., Wang, H., Puigvehi, M., Maeda, M., et al. (2023) · Gut · doi:10.1136/gutjnl-2021-325918 · Cited by 253
Pinato, D. J., Murray, S. M., Forner, A., Kaneko, T., Fessas, P., Toniutto, P., Mínguez, B., Cacciato, V., Avellini, C., Diaz, A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003311 · Cited by 228
Luna, A., Elloumi, F., Varma, S., Wang, Y., Rajapakse, V. N., Aladjem, M. I., Robert, J., Sander, C., Pommier, Y., & Reinhold, W. C. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa968 · Cited by 208
A membrane-associated MHC-I inhibitory axis for cancer immune evasion
Chen, X., Lu, Q., Zhou, H., Liu, J., Nadorp, B., Lasry, A., Sun, Z., Lai, B., Rona, G., Zhang, J., et al. (2023) · Cell · doi:10.1016/j.cell.2023.07.016 · Cited by 205
Single-Cell RNA Sequencing to Dissect the Immunological Network of Autoimmune Myocarditis.
Hua, X., Hu, G., Hu, Q., Chang, Y., Hu, Y., Gao, L., Chen, X., Yang, P.-C., Zhang, Y., Li, M., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.043545 · Cited by 201
The Multiple Roles of Interferon Regulatory Factor family in Health and Disease
Wang, L., Zhu, Y., Zhang, N., Xian, Y., Tang, Y., Ye, J., Reza, F., He, G., Wen, X., & Jiang, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01980-4 · Cited by 178
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Lukhele, S., Abd-Rabbo, D., Guo, M., Shen, J., Elsaesser, H. J., Quevedo, R., Carew, M., Gadalla, R., Snell, L. M., Mahesh, L., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.020 · Cited by 144
Mpakali, A., & Stratikos, E. (2021) · Cancers · doi:10.3390/cancers13010134 · Cited by 137
Deng, G., Zhou, L., Wang, B., Sun, X., Zhang, Q., Chen, H., Wan, N., Ye, H., Wu, X., Sun, D., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004874 · Cited by 126
Tumor immune evasion through loss of MHC class-I antigen presentation
Sarı, G., & Rock, K. L. (2023) · Current Opinion in Immunology · doi:10.1016/j.coi.2023.102329 · Cited by 124
Self-citationBalasubramanian, A., John, T., & Asselin-Labat, M.-L. (2022) · Biochemical Society Transactions · doi:10.1042/bst20210961 · Cited by 79
Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy
Xu, Y., Chen, C., Guo, Y., Hu, S., & Sun, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.848327 · Cited by 78
Future Challenges in Cancer Resistance to Immunotherapy
van Elsas, M. J., van Hall, T., & van der Burg, S. H. (2020) · Cancers · doi:10.3390/cancers12040935 · Cited by 74
Bashash, D., Zandi, Z., Kashani, B., Pourbagheri‐Sigaroodi, A., Salari, S., & Ghaffari, S. H. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30575 · Cited by 65
Huber, F., & Bassani‐Sternberg, M. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01208-8 · Cited by 64
Mitochondrial respiration contributes to the interferon gamma response in antigen-presenting cells
Kiritsy, M. C., McCann, K. J., Mott, D., Holland, S. M., Behar, S. M., Sassetti, C. M., & Olive, A. J. (2021) · eLife · doi:10.7554/elife.65109 · Cited by 59
Tumour neoantigen mimicry by microbial species in cancer immunotherapy
Boesch, M., Baty, F., Rothschild, S. I., Tamm, M., Joerger, M., Früh, M., & Brutsche, M. H. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01365-2 · Cited by 58
Playing hide and seek: Tumor cells in control of MHC class I antigen presentation
Jongsma, M. L. M., Neefjes, J., & Spaapen, R. M. (2021) · Molecular Immunology · doi:10.1016/j.molimm.2021.05.009 · Cited by 56
Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers
Lehrich, B. M., Delgado, E. R., Yasaka, T. M., Liu, S., Cao, C., Liu, Y., Taheri, M. N., Guan, X., Koeppen, H., Singh, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60457-2 · Cited by 52
Hierarchy of signaling thresholds downstream of the T cell receptor and the Tec kinase ITK
Gallagher, M. P., Conley, J. M., Vangala, P., Garber, M. G., Reboldi, A., & Berg, L. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025825118 · Cited by 51
Self-citationRETRACTED ARTICLE: Hurdles to breakthrough in CAR T cell therapy of solid tumors
Marofi, F., Achmad, H., Bokov, D., Abdelbasset, W. K., Alsadoon, Z., Chupradit, S., Suksatan, W., Shariatzadeh, S., Hasanpoor, Z., Yazdanifar, M., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02819-x · Cited by 47
RetractedA Novel Gene Prognostic Signature Based on Differential DNA Methylation in Breast Cancer
Zhu, C., Zhang, S., Liu, D., Wang, Q., Yang, N., Zheng, Z., Wu, Q., & Zhou, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.742578 · Cited by 42
Competition between two HUSH complexes orchestrates the immune response to retroelement invasion
Danac, J. M. C., Matthews, R. E., Gungi, A., Qin, C., Parsons, H. T., Antrobus, R., Timms, R. T., & Tchasovnikarova, I. A. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.06.020 · Cited by 40
Expression of PD-L1 in EBV-associated malignancies
Li, X., & Zhang, W. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107553 · Cited by 37
Friedman, L. A., Bullock, T. N. J., Sloan, E. A., Ring, K. L., & Mills, A. M. (2020) · Modern Pathology · doi:10.1038/s41379-020-00682-w · Cited by 36
Paschen, A., Melero, I., & Ribas, A. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070220-111016 · Cited by 36
Dibbern, M. E., Bullock, T. N. J., Jenkins, T. M., Duska, L., Stoler, M. H., & Mills, A. M. (2020) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001506 · Cited by 36
Reduced MHC Class I and II Expression in HPV−Negative vs. HPV−Positive Cervical Cancers
Evans, A. M., Salnikov, M. Y., Tessier, T. M., & Mymryk, J. S. (2022) · Cells · doi:10.3390/cells11233911 · Cited by 31
Ma, J., Miao, H., Zhang, H., Ren, J., Qu, S., Da, J., Xu, F., & Zhao, H. (2021) · Diagnostic Pathology · doi:10.1186/s13000-021-01108-0 · Cited by 31
Inference of age-associated transcription factor regulatory activity changes in single cells
Maity, A. K., Hu, X., Zhu, T., & Teschendorff, A. E. (2022) · Nature Aging · doi:10.1038/s43587-022-00233-9 · Cited by 30
Purbey, P. K., Seo, J., Paul, M. K., Iwamoto, K. S., Daly, A. E., Feng, A., Champhekar, A. S., Langerman, J., Campbell, K. M., Schaue, D., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114289 · Cited by 29
Xu, Y., Nipper, M. H., Dominguez, A. A., Ye, Z., Akanuma, N., Lopez, K. M., Deng, J., Arenas, D., Sánchez, A., Sharkey, F. E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45097-2 · Cited by 27
Oncolytic Virotherapy: The Cancer Cell Side
Ehrlich, M., & Bacharach, E. (2021) · Cancers · doi:10.3390/cancers13050939 · Cited by 26
Genome-wide CRISPR/Cas9 screening for drug resistance in tumors
Zhang, Z., Wang, H., Yan, Q., Cui, J., Chen, Y., Ruan, S., Yang, J., Wu, Z., Han, M., Huang, S., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1284610 · Cited by 26
Development of an IFNγ response‐related signature for predicting the survival of cutaneous melanoma
Hu, B., Wei, Q., Li, X., Ju, M., Wang, L., Zhou, C., Chen, L., Li, Z., Wei, M., He, M., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3438 · Cited by 25
MDM2 inhibitors in cancer immunotherapy: Current status and perspective
Zeng, Q., Zeng, S., Dai, X., Ding, Y., Huang, C., Ruan, R., Xiong, J., Tang, X., & Deng, J. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101279 · Cited by 25
Fan, S., & Wang, L. (2021) · Bioengineered · doi:10.1080/21655979.2021.2001905 · Cited by 24
KDM6A regulates immune response genes in multiple myeloma
Dupéré-Richer, D., Riva, A., Maji, S., Barwick, B. G., Román, H. L. C., Sobh, A., Quickstad, G., Li, J., De, U., Piper, C., et al. (2024) · Blood · doi:10.1182/blood.2024024518 · Cited by 23
Villéger, R., Chulkina, M., Mifflin, R. C., Markov, N. S., Trieu, J. A., Sinha, M., Johnson, P. R., Saada, J. I., Adegboyega, P. A., Luxon, B. A., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02066-0 · Cited by 20
Niu, Y., Jiang, H., Yin, H., Wang, F., Hu, R., Hu, X., Peng, B., Shu, Y., Li, Z., Chen, S., et al. (2022) · Diabetes · doi:10.2337/db21-0857 · Cited by 20
Tackling Resistance to Cancer Immunotherapy: What Do We Know?
Gondhowiardjo, S. A., Handoko, H., Jayalie, V. F., Apriantoni, R., barata, A. R., Senoaji, F., Utami, I. J. W., Maubere, F., Nuryadi, E., & Giselvania, A. (2020) · Molecules · doi:10.3390/molecules25184096 · Cited by 18
Huang, L., Qin, S., Xia, L., Ma, F., & Chen, L. (2023) · Cancer Medicine · doi:10.1002/cam4.5892 · Cited by 16
IRF-2 inhibits cancer proliferation by promoting AMER-1 transcription in human gastric cancer
Chen, Y., Luo, S.-N., Wu, H., Zhang, N., Dong, L., Liu, T., Liang, L., & Shen, X. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03275-0 · Cited by 16
Tryptophan metabolism promotes immune evasion in human pancreatic β cells
Rachdi, L., Zhou, Z., Berthault, C., Lourenço, C., Fouque, A., Domet, T., Armanet, M., You, S., Peakman, M., Mallone, R., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104740 · Cited by 15
Cuttano, R., Colangelo, T., Guarize, J., Dama, E., Cocomazzi, M. P., Mazzarelli, F., Melocchi, V., Palumbo, O., Marino, E., Belloni, E., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01394-1 · Cited by 13
Sarcoma Common MHC-I Haplotype Restricts Tumor-Specific CD8+ T Cell Response
Mosca, L., Angelis, A. D., Ronchi, A., Chiara, A. D., Fazioli, F., Ruosi, C., Altucci, L., Conte, M., & de Nigris, F. (2022) · Cancers · doi:10.3390/cancers14143414 · Cited by 12
Shapiro, I. E., Maschke, C., Michaux, J., Pak, H., Wessling, L., Verkerk, T., Spaapen, R. M., & Bassani‐Sternberg, M. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2025.100951 · Cited by 11
Cho, H., & Kim, K. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2348656 · Cited by 11
Liu, M., Wang, T., & Li, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020625 · Cited by 10
Sauerer, T., Lischer, C., Weich, A., Berking, C., Vera, J., & Dörrie, J. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.785662 · Cited by 9
Association of HLA-A*11:01, -A*24:02, and -B*18:01 with Prostate Cancer Risk: A Case-Control Study
Manca, M. A., Simula, E. R., Cossu, D., Solinas, T., Madonia, M., Cusano, R., & Sechi, L. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015398 · Cited by 9
Expanded Alternatives of CRISPR–Cas9 Applications in Immunotherapy of Colorectal Cancer
Arroyo-Olarte, R. D., Mejía-Muñoz, A., & León‐Cabrera, S. (2023) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-023-00680-z · Cited by 8
Sarı, G., Dhatchinamoorthy, K., Orellano, L. A. A., Ferreira, L. M., Brehm, M. A., & Rock, K. L. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03187-5 · Cited by 8
Self-citationNohara, L. L., Ellis, S. L. S., Dreier, C., Dada, S., Saranchova, I., Choi, K. B., Munro, L., Pfeifer, C. G., Haddad, E. A., Coyle, K. M., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1119607 · Cited by 8
Sun, Y., Malaer, J. D., & Mathew, P. A. (2019) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2019.29 · Cited by 8
Identification of DDX60 as a Regulator of MHC-I Class Molecules in Colorectal Cancer
Geng, N., Hu, T., & He, C. (2022) · Biomedicines · doi:10.3390/biomedicines10123092 · Cited by 7
Validation and functional follow‐up of cervical cancer risk variants at the HLA locus
Eisenblätter, R., Seifert, F., Schürmann, P., Beckhaus, T., Hanel, P., Jentschke, M., Böhmer, G., Strauß, H., Hirchenhain, C., Schmidmayr, M., et al. (2024) · HLA · doi:10.1111/tan.15597 · Cited by 7
Cancer gene identification from RNA variant allelic frequencies using RVdriver
Black, J. R., Jones, T. P., Martínez‐Ruiz, C., Litovchenko, M., Puttick, C., Swanton, C., & McGranahan, N. (2025) · Genome biology · doi:10.1186/s13059-025-03557-y · Cited by 7
Khalil, M. I., Wang, J., Vu, L., Yang, C., Yin, C., Chadha, S., Nabors, H., Vocelle, D. B., May, D. G., Chrisopulos, R. J., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2525730123 · Cited by 6
Chang, K., Han, K. S., Qiu, W., Hu, Z., Chen, X., Chen, X., Xie, X., Wang, S., Hu, C., & Mao, H. (2021) · Molecular Immunology · doi:10.1016/j.molimm.2021.04.020 · Cited by 6
Shao, L., Srivastava, R., Delgoffe, G. M., Thorne, S. H., & Sarkar, S. N. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0573 · Cited by 5
Endothelial Elavl1 Is Required for CD8 T-Cell Persistence in Atherosclerosis
Nicholas, S.-A. E., Helming, S. B., Ménoret, A., Pathoulas, C. L., Xu, M. M., Hensel, J. A., Kimble, A. L., Heineman, B. D., Jellison, E. R., Reese, B., et al. (2026) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.125.323674 · Cited by 5
Mei, W., Ding, Y., Bian, C., Jia, Y., Qu, C. F., Fang, Z., Li, J., Liu, S., Sun, H., Xu, X., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.10.079 · Cited by 4
Xu, H., Qu, X., & Wang, X. (2024) · Journal of Hypertension · doi:10.1097/hjh.0000000000003887 · Cited by 4
Hou, J., Li, M. C., Lu, Q., Hao, W., Liu, L. H., Gan, Z., Huang, B., Huang, W. S., Wang, L., Li, L., et al. (2025) · Aquaculture · doi:10.1016/j.aquaculture.2025.742455 · Cited by 4
Jiang, X., Asad, M., Li, L., Sun, Z., Milanese, J., Liao, B., & Wang, E. (2020) · Quantitative Biology · doi:10.1007/s40484-020-0212-7 · Cited by 4
Evoking the Cancer-immunity cycle by targeting the tumor-specific antigens in Cancer immunotherapy
Guo, X., Bai, J., Wang, X., Guo, S., Shang, Z., & Shao, Z. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114576 · Cited by 3
Messing with Signal 1: How Perturbed MHC Class I Antigen Presentation Contributes to Cancer
Lawand, M., Rayess, S. A., Jaber, R., & Endert, P. V. (2026) · Cells · doi:10.3390/cells15070653 · Cited by 3
Park, C., Wong, T. L., & K, S. (2026) · Carcinogenesis · doi:10.1093/carcin/bgag040 · Cited by 3
De, S., & Ehrlich, M. (2024) · Genes · doi:10.3390/genes15091193 · Cited by 3
Perspective Chapter: The Role of Interferon Gamma in Clinical Medicine
Rakityanskaya, I. A., Ts, R., Андреевна, К. А., Balasaniants, G. S., Каприн, А. Д., Fi, E., Kir’janova, V. V., Korzhenevskaja, T. B., Barbinov, D. V., Ignatovskij, A. V., et al. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105476 · Cited by 3
The role of the major histocompatibility complex (MHC) class I in prostate cancer therapy: A review
Emtiazi, N., Zolfi, E., Mehr, F. K., & Moradi, Y. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104897 · Cited by 2
Allela, O. Q. B., Shareef, A., Sameer, H. N., Yaseen, A., Athab, Z. H., & Mm, A. (2026) · Current Medical Science · doi:10.1007/s11596-026-00227-3 · Cited by 2
New approaches to vaccines for cancer
Chavda, V. P., Acharya, D., Malla, S., Ashby, C. R., & Tiwari, A. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18564-9.00009-6 · Cited by 2
Xu, R., He, D., Sun, R., Zhou, J., Xin, M., Liu, Q., Dai, Y., Li, H., Zhang, Y., Li, J., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06222-x · Cited by 2
Qiu, Y., Zhang, R., Liu, S., Wu, L., Wang, Y., Cai, W., He, P., Cai, Q., Lin, Y., Guo, W., et al. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-02150-2 · Cited by 1
Tian, L., Zhang, M., Guo, Y., Chang, S., Chen, Z. K., & Zhou, H. (2025) · Immunology · doi:10.1111/imm.70082 · Cited by 1
Jin, W. Y., Jin, P., Tan, Y., Lou, J., Li, F., Tao, J., Wang, D., Zhang, Y., Yu, Y., Dong, F., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118490 · Cited by 1
Commentary: Not only SMART clinically, but translationally!
Pass, H. I. (2019) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2019.09.101 · Cited by 1
Cell-extrinsic effects of Irf2 on cDC2 developmentPreprint
O’Connor, K., Liu, T., Kim, S. K., Murphy, T. L., & MURPHY, K. M. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.24.554658 · Cited by 1
CREB5 promotes immunotherapy resistance via tumor-intrinsic collagen matrix depositionPreprint
Tiwari, P., Colvin, K. J., Kim, S. Y., Kammula, A. V., Chinai, J. M., Alfaiate, N., Revach, O., Kistler, E. N., Heo, S., Anderson, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.22.649109 · Cited by 1
Lu, B., Xu, H., Ding, M., & Yan, C.-Y. (2021) · Journal of Biomaterials and Tissue Engineering · doi:10.1166/jbt.2021.2769
Hepatokine ERAP1 impairs skeletal muscle insulin sensitivity via ADRB2/PKA pathwayPreprint
Guo, F., Niu, Y., Jiang, H., Yin, H., Wang, F., Hu, X., & Chen, S. (2020) · Research Square · doi:10.21203/rs.3.rs-37586/v1
The Canadian Society for Immunology's 34th annual meeting 2022: symposia minireview
Carter, E. B., Pugh-Toole, M., Kabil, A., Boudreau, J. E., & Nersesian, S. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiad002
Mak, Q. (2024) · Theoretical and Natural Science · doi:10.54254/2753-8818/32/20240737
Paired CRISPR screens to map gene regulation in cis and transPreprint
Xue, X., Gajic, Z. Z., Caragine, C. M., Legut, M., Walker, C. R., Kim, J. Y. S., Wang, X., Yan, R. E., Wessels, H., Lu, C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.27.625752
Mestrallet, G., Pierga, A., & Frémont, P. (2026) · Peer Community Journal · doi:10.24072/pcjournal.758
Cuttano, R., Colangelo, T., Guarize, J., Dama, E., Cocomazzi, M. P., Mazzarelli, F., Melocchi, V., Palumbo, O., Marino, E., Belloni, E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22606799
Cuttano, R., Colangelo, T., Guarize, J., Dama, E., Cocomazzi, M. P., Mazzarelli, F., Melocchi, V., Palumbo, O., Marino, E., Belloni, E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22606775
Cuttano, R., Colangelo, T., Guarize, J., Dama, E., Cocomazzi, M. P., Mazzarelli, F., Melocchi, V., Palumbo, O., Marino, E., Belloni, E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22606802
Cuttano, R., Colangelo, T., Guarize, J., Dama, E., Cocomazzi, M. P., Mazzarelli, F., Melocchi, V., Palumbo, O., Marino, E., Belloni, E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22606784
Metadata
- Authors
- Kriegsman, B. A., Vangala, P., Chen, B. J., Meraner, P., Brass, A. L., Garber, M., & Rock, K. L.
- Affiliations
- University of Massachusetts Chan Medical School (US)
- Corresponding author
- Rock, Kenneth L
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-10-01
- Volume
- 203
- Issue
- 7
- Pages
- 1999-2010
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- PMC
- PMC6761035
- OpenAlex
- W2970242544
- Cited by
- 114
- References
- 64
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 17 · 2023: 23 · 2022: 18 · 2021: 19 · 2020: 10 · 2019: 2
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- Funders
- National Institute of General Medical Sciences (T32GM107000)
- National Institute of Allergy and Infectious Diseases (R01AI145932, R01AI114495, T32AI095213)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Keywords
- IRF2, tumor immune evasion, MHC class I antigen presentation, PD-L1, immunoproteasome, TAP, ERAP1, CD8+ T cells, IRF1, interferon-stimulated genes, transcriptional repressor, cancer immunotherapy
- MeSH terms
- HeLa Cells, Humans, Neoplasm Proteins, Neoplasms, Histocompatibility Antigens Class I, Down-Regulation, Gene Expression Regulation, Neoplastic, Antigen Presentation, CD8-Positive T-Lymphocytes, Tumor Escape, Interferon Regulatory Factor-2, HEK293 Cells, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.